当前位置:首页 >财报库 > 报告详情

嘉德诺Cardinal Health(CAH)2024年第三季度财报(英文版)(47页).pdf

上传人: Y**** 编号:182700 2024-11-06 47页 558.88KB

下载:

1、Table of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549Form 10-QQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended September 30,2024orTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCH

2、ANGE ACT OF 1934For the transition period from _ to _Commission File Number:1-11373Cardinal Health,Inc.(Exact name of registrant as specified in its charter)Ohio31-0958666(State or other jurisdiction ofincorporation or organization)(IRS EmployerIdentification No.)7000 Cardinal Place,Dublin,Ohio43017

3、(Address of principal executive offices)(Zip Code)(614)757-5000(Registrants telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:Title of each classTrading Symbol(s)Name of each exchange on whichregisteredCommon shares(without par value)CAHNew York Stock Exc

4、hangeIndicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of1934 during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject tosuch f

5、iling requirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T(232.405 of this chapter)during the preceding 12 months(or for such shorter period that

6、the registrant was required tosubmit such files).Yes No Indicate by check mark whether the registrant is a large accelerated filer,an accelerated filer,a non-accelerated filer,a smaller reportingcompany,or an emerging growth company.See the definitions of“large accelerated filer,”“accelerated filer,

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文是Cardinal Health公司2025财年第一季度10-Q表格报告,主要内容包括: 1. 收入:2025财年第一季度,公司总收入为523亿美元,较2024财年同期下降4%,主要原因是OptumRx合同到期。 2. 经营收益:2025财年第一季度,公司GAAP经营收益为5.68亿美元,而2024财年同期为亏损3200万美元。非GAAP经营收益为6.25亿美元,较2024财年同期增长12%,主要原因是品牌和专科药品销售增长。 3. 每股收益:2025财年第一季度,公司GAAP每股收益为1.70美元,而2024财年同期为亏损0.05美元。非GAAP每股收益为1.88美元,较2024财年同期增长9%。 4. 现金及现金等价物:截至2025财年第一季度末,公司现金及现金等价物余额为29亿美元,而2024财年同期为51亿美元。 5. 重大发展:公司宣布与OptumRx的药品分销合同将于2024年6月到期,并宣布收购Integrated Oncology Network和Specialty Networks,以扩大其在关键治疗领域的业务。 6. 风险因素:公司面临的主要风险包括药品供应短缺、药品价格波动、诉讼风险等。
2024年第一季度,卡迪纳尔健康公司收入下降的原因是什么? 2024年第一季度,卡迪纳尔健康公司的非GAAP经营收益为何增加? 2024年第一季度,卡迪纳尔健康公司的现金及等价物余额为何减少?
客服
商务合作
小程序
服务号
折叠